|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-11-3335.
IMMUNOBIOLOGY
From the Department of Experimental Medicine, Section
of Human Anatomy, Genoa University, Genoa, Italy; the
Department of Experimental Oncology, European Institute of Oncology,
Milan, Italy; the Department of Clinical and Experimental
Medicine, Section of Internal Medicine and Oncological Sciences,
Perugia University, Perugia, Italy; and the Fondazione
Italiana per la Ricerca sul Cancro, Institute for Molecular Oncology,
Milan, Italy.
The promyelocytic leukemia gene, PML,
is a growth and transformation suppressor. An additional role for
PML as a regulator of major histocompatibility complex
(MHC) class I antigen presentation has been proposed in a
murine model, which would account for evasion from host immunity of
tumors bearing malfunctioning PML, such as acute promyelocytic
leukemia. Here we investigated a possible role of
PML for the control MHC class I expression in human cells. PML function was perturbed in human cell lines either by
PML/RAR The promyelocytic leukemia (PML)
gene has been identified in acute promyelocytic leukemia (APL)
patients, in whom it is fused to the retinoic acid receptor A novel mechanism mediated by PML has been proposed recently, based on
the observation that murine PML (mPML) regulates the expression of
major histocompatibility complex (MHC) class I
molecules.18 An mPML mutant was isolated that
produced a truncated form of mPML protein in an MHC class I-negative
tumor cell line. This mutant acted as a dominant-negative regulator and
was considered responsible for an antigen-processing defect that caused
a decreased MHC class I expression.18 In addition, a mPML
isoform, called F12 (exons 1-4, 6, and 7 and part of exon 9 of the
mPML gene), was shown to up-regulate MHC class I expression
in an MHC class I-negative tumor cell line and in untransformed murine
fibroblasts.18 This mechanism would allow tumors bearing
malfunctioning PML to escape the host immune surveillance. Thus, APL
cells that harbor mutated PML should display a decreased
expression of MHC class I molecules. However, expression of HLA A-B-C
has been found in APLs19 at the same extent as in other
acute myeloid leukemias that do not harbor PML
alterations.20
Following these controversial results, we studied the relationship
between PML and MHC class I in human cell lines. To this end, we
affected the function of PML in 2 ways, that is, by inducing expression of the PML/RAR Alternatively, we asked whether PML could be involved in the
up-regulation of MHC class I above its constitutive level. To this end,
we studied whether an impaired or aberrant function of PML (induced by
RNA interference or by the PML mutant) would affect the ability of
We conclude that, in human cell lines, PML is not directly involved in
the regulation of MHC class I expression.
PML mutants and expression vectors
A human homolog of the murine F12dG PML
mutant18 was constructed. The murine F12dG
mutant has a single base deletion in exon 3 (a deletion of a G at
position 962 of the murine PML-F12 sequence)18
that corresponds to position 875 relative to the first nucleotide of
the start codon. F12 is an mPML isoform that comprises exons 1 to 4, 6, and 7 and part of exon 9.18 The
point deletion in exon 3 causes a frameshift and early translational termination of the PML protein in exon 3. Because of the high homology
between murine and human PML exons, the G to be deleted was
easily identified in the human PML cDNA sequence and was
found at position 958 relative to the first nucleotide of the human PML start codon. By site-directed mutagenesis, this G was
deleted in the GFP-PML construct within the pcDNA3.1 vector.
The QuickChange Site-Directed Mutagenesis Kit from Stratagene (La
Jolla, CA) was used, and the following oligonucleotide primers
containing the desired mutation were synthesized by Invitrogen:
5'-GGCTGGGCCGCCTGATGCTGTGCTGCAGCGC-3' and its complementary
5'-GCGCTGCAGCACAGCATCAGGCGGCCCAGCC-3'. The new mutated construct was
checked by direct nucleotide sequencing using the Dye Terminator Cycle
Sequencing Kit (ABI PRISM; Perkin-Elmer Applied Biosystems, Norwalk,
CT). The following sequencing primers were used: the upstream forward
oligonucleotides 5'-GCGCTCCTTGACAGCAGC-3' and
5'-TGCAGGAGCAGGATAGATC-3', and the downstream reverse oligonucleotides 5'-CTGGGCTGTCGTTGTATTGG-3' and 5'-GCGCACCTTGAACTCGTCG-3'. Sequences were resolved and analyzed using the ABI 373A Sequence Apparatus (Perkin-Elmer Applied Biosystems).
Short-interfering (si)-RNA preparation for RNA
interference
Cell cultures and transfections Cell lines used were as follows: HeLa and HEK293 from the American Type Culture Collection (ATCC, Rockville, MD), and the neuroblastoma cell lines SK-N-BE2(c) and ACN kindly provided by Dr V. Pistoia (Genoa, Italy). Cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, and antibiotics.Transfection of cells with different PML isoforms, cloned in either pBABE or in pcDNA3.1 vectors, was performed with Lipofectamine 2000 (Invitrogen) in 24-well plates. DNA (1 µg) was dispensed in each well. Transfection of siRNA duplexes for RNA interference was carried out with Oligofectamine (Invitrogen), following the guidelines of the manufacturer for 24-well plates and using 0.84 µg siRNA duplex per well. Oligofectamine was used in cotransfection experiments, when both PML isoforms and siRNA duplexes were transfected. No reduction in transfection efficiency for PML was observed in comparison with transfections carried out with Lipofectamine 2000. Flow cytometric immunofluorescence Cells were incubated with mouse monoclonal antibodies (mAbs) to MHC class I followed by phycoerythrin (PE)-labeled goat anti-mouse IgG mAb (GAM, Southern Biotechnology Associates, Birmingham, AL). Anti-MHC class I mAbs were W6.32 ( 2a, ATCC), 3A3 (µ), and A2 (1). The last 2 mAbs were
produced in our laboratory and are specific for a monomorphic epitope
of MHC class I. Controls were provided by cells incubated with
isotype-matched mAbs of irrelevant specificity followed by PE-labeled
GAM mAb. Samples were analyzed using a FacsCalibur flow cytometer and
CellQuest software (Becton Dickinson, Milan, Italy).
Fluorescence microscopy Control and transfected cells grown on glass coverslips in 24-well plates were processed for immunostaining with the following primary antibodies: PG-M3, a mouse mAb that recognizes all PML isoforms since its epitope lies in the amino terminal region of human PML (residues 37-51)26 and SP100 (Santa Cruz Biotechnology, Heidelberg, Germany). Fluorochrome-conjugated secondary antibodies included GAM-Alexa 594 (Molecular Probes, Eugene, OR), donkey antimouse fluorescein isothiocyanate (FITC), and donkey antigoat cytochrome 3 (Cy3) (Jackson ImmunoResearch Laboratories, West Grove, PA).Cells were fixed with 3.7% paraformaldehyde for 10 minutes at room
temperature followed by 0.1% Triton X-100 for 10 minutes at room
temperature (for PML), or with methanol for 3 minutes at
MHC class I expression is not affected by a dominant-negative mutant of PML We studied whether an impairment of PML function would affect surface expression of MHC class I molecules. A first approach to inhibit PML was to transfect cells with the APL-associated fusion gene PML/RAR . The chimeric PML/RAR protein acts as a dominant-negative oncogene by delocalizing PML molecules to aberrant microspeckled nuclear structures.11 In Figure
1, results with HeLa cells are shown.
Controls were provided by vector alone or PML-transfected
cells. As shown by flow cytometric measurements of GFP fluorescence,
39% of the cells were transfected with PML and 34% with
PML/RAR MHC class I expression of PML/RAR-expressing cells had a mean fluorescence value almost identical to that of untransfected and of PML-transfected cells. Detection of MHC
class I molecules with antibodies different from W6.32, such as the 3A3
and A2 mAb, yielded the same results (not shown). Time-course measurements of MHC class I expression were also carried out, from 16 hours after transfection (when GFP reached a significant level of
detection) up to the seventh day, and provided identical results (not
shown). The microscopic examination of cells grown on glass slides and
stained with anti-PML mAb demonstrated the dominant action of
PML/RAR that disassembled PML molecules in NBs leading to a diffuse
microspeckled pattern. At variance, PML-transfected cells
displayed classical NBs that were larger than normal NBs of control
cells (eg, compare the GFP-positive cell with the GFP-negative cell, in
second row of Figure 1). Experiments carried out with HEK293 cells also
indicated that the surface amount of MHC class I molecules is not
affected by PML/RAR expression (not shown).
MHC class I expression is not affected by PML-specific RNA interference RNA interference is a process of sequence-specific gene silencing initiated by double-stranded RNA that is homologous to the silenced gene.27 The mediators of sequence-specific messenger RNA degradation are 21-nucleotide short-interfering RNAs (siRNA) generated by ribonuclease III cleavage from longer double-stranded (ds) RNAs.28 Based on this physiologic mechanism, an in vitro gene silencing technique that introduces duplexes of 21-nucleotide siRNA homologous to the down-regulated gene has been developed for mammalian cells.21 We used this technique for silencing PML.In Figure 2, the effects of PML-specific
RNA interference on surface MHC class I expression are shown, both in
control cells and in GFP-PML-transfected HeLa cells.
RNA interference was effective.
Microscopic analyses of the distribution of PML and SP100, which colocalizes with PML in NBs, demonstrated the complete disappearance of NBs in 97% of the cells. To support further the efficiency of PML silencing by siRNA, we performed experiments in which GFP-PML and siRNA duplexes were cotransfected. In these experimental conditions the percentage of GFP-positive cells decreased from 35% to 2%, and the negative cells (98%) did not display a reduced GFP fluorescence but, instead, a completely undetectable GFP. This indicates the complete absence of any exogenously expressed PML protein in these cells and, thus, the absence of endogenous PML is proved further. However, despite the absence of PML expression, surface expression of MHC class I molecules was unchanged, as observed from 48 hours after transfection (when the effect of RNA interference became significant; Figure 2) up to the fifth day (not shown). MHC class I expression is not altered by PML mut ex3 In the work mentioned previously,18 a specific mPML mutant termed "F12dG" was shown to induce an antigen-processing defect by decreasing MHC class I expression in murine cells. This mutant has a point deletion in exon 3 of the mPML gene that causes a frameshift and translational termination of PML at exon 3. It has been proposed that the mechanism responsible for MHC class I down-regulation is a dominant-negative action of F12dG that impairs the physiologic activity of wild-type PML, possibly by dimerizing with wt PML and thus interfering with its function.18We observed that impairment of PML function had no effect on the
surface expression of MHC class I. Therefore, we reasoned that
F12dG could code for a protein that actively affects the pathway of MHC class I regulation, instead of negatively regulating the
function of PML. F12dG is much shorter than wt mPML and could display a
different tertiary structure (F12dG is composed of 308 amino acids
[aa's], while the 2 mPML isoforms deposited on Genbank [accession
nos. U33626 and NM_008884] consist of 808 aa's). In addition, F12dG
contains a 16-aa string at its C-terminus that is not present in wt
mPML; this could account for some specific activity. Thus, we
constructed a GFP-tagged human homolog of F12dG, "PML mut ex3" (see details in "Materials and
methods"), and transfected it into HeLa, HEK 293, ACN, and
SK-N-BE2(c) cell lines. Sequences of the human PML mutant (PML mut ex3)
and the mPML mutant (F12dG) are compared in Figure
3A. Transfected cells exhibited a
completely different pattern of PML localization, following
immunofluorescence staining with anti-PML mAb, as shown in Figure 3.
The localization of PML molecules in NBs was replaced by perinuclear or
cytoplasmic dots, which were larger and in lower numbers (eg, HeLa and
HEK293) or smaller but more numerous (eg, ACN and SK-N-BE2(c)). Whether the dots were fewer/larger or more/smaller did not depend on the cell
type, but rather on the cell density of the monolayer. Cells not
surrounded by neighboring elements and able to extend large cytoplasmic
expansions displayed a thicker and more speckled PML distribution. The
almost complete absence of other PML molecules within NBs suggests a
dominant-negative action of PML mut ex3. Yet, PML mut ex3 did not
affect the expression of MHC class I, because transfected cells did not
exhibit a decreased expression of surface MHC class I molecules. This
result is shown in Figure 3B by flow cytometric GFP/MHC class I
bivariate plots of ACN cells, and it is superimposable to data obtained
with all cell lines tested (not shown). Time-course measurements of MHC
class I expression were also carried out, from 16 hours after
transfection (when GFP reached a significant level of detection) up to
the seventh day, and provided identical results (not shown).
-IFN to
up-regulate MHC class I expression.
HEK293 and SK-N-BE2(c), 2 cell lines that display low surface
MHC class I expression, were treated with 1000 U/mL
The purpose of our study was to clarify whether PML regulates MHC class I-mediated antigen presentation in human cells, as proposed previously in a murine model.18 According to this hypothesis, since expression of PML is altered in several solid tumors30-32 (though the gene mutation patterns are not established yet2), it could be envisaged that tumorigenesis of cells bearing aberrant PML may be caused by inactivation of PML-regulated tumor suppressive pathways related to cell-cycle control and apoptosis,13-17,33 but also by their invisibility to the immune system. On the other hand, APL cells, harboring a well-known PML inactivation, do not display reduced MHC class I expression.19 It is possible that in human cells PML behaves differently from murine cells, although the protein itself bears a very high homology in the 2 systems. In this study PML function in human cell lines was inhibited by
transfecting cells with the fusion gene PML/RAR Once shown that impairment of PML function did not affect surface expression of MHC class I molecules on human cells, we followed an alternative route suggested by the murine model.18 A specific mPML mutant called F12dG was shown to decrease MHC class I expression by a dominant-negative action.18 Since we had observed that impairment of PML function had no effect on surface expression of MHC class I, we asked whether F12dG could code for a protein that actively affects the pathway of MHC class I regulation, instead of negatively regulating the function of PML. F12dG has a point deletion in exon 3 of the mPML gene that causes a frameshift and early truncation of the protein. Thus, F12dG is much shorter than wt mPML and may display a different tertiary structure. In addition, F12dG contains a 16-aa string at its C-terminus that is not present in wt mPML; this could account for some specific activity. We constructed a human homolog of F12dG ("PML mut ex3") and transfected it into human cell lines. At variance from the mutant F12dG in murine cells, the human mutant PML mut ex3 did not affect surface expression of MHC class I. Transfected cells exhibit a completely different pattern of PML localization. The typical distribution of PML molecules in NBs is replaced by perinuclear or cytoplasmic large dots. The cytoplasmic localization pattern of PML mut ex3 could be due, at least in part, to a loss of the nuclear localization signal (NLS) domain in exon 6, caused by a truncation of the protein in exon 3. The almost complete absence of PML-NBs suggests a dominant-negative action of PML mut ex3 molecules. The mechanism of dominant-negative regulation is unclear. In murine cells the mutant F12dG protein was suggested to dimerize with wt PML,18 thus interfering with its function. This could be possible also in our case, as the PML mut ex3 protein retains the first 91 aa's of 95 aa's of the whole coiled-coil region, which is responsible for dimerization. Since we did not observe a down-regulation of MHC class I expression in human cells either by affecting PML or by transfecting a human homolog of F12dG, we focused on another experimental approach described by Zheng et al.18 They found that a DNA sequence, called F12, was able to restore surface MHC class I expression in a tumor cell line that had lost it (ReB7), as well as in NIH3T3 cells derived from Stat-1-deficient mice that do not exhibit detectable surface MHC class I. DNA sequencing revealed that F12 cDNA is an isoform of PML comprising exons 1-4, 6, and 7, and part of exon 9 of the mPML gene. Accordingly, we searched for a human homolog of F12 to determine whether transfection of "human F12" may up-regulate MHC class I expression. However, no human PML isoform expressing the same pattern of exon distribution has been found yet in human cells, as indicated by a recent review that summarizes all data on PML isoforms and splice variants.3 We also performed a BLAST search of the theoretical cDNA sequence of "human F12" (obtained by replacing the murine exons with the corresponding human exons) against the human expression sequence tags (ESTs) database (Genbank). No matches were found. The lack of expression of a human form of F12 in human cells ruled out any rationale for this issue. An additional consideration excludes the existence of a "human F12" protein that regulates MHC class I in human cells. Should such a molecule exist, it would have been knocked down in the RNA interference experiments, since the siRNA sequence chosen to silence all forms of PML was on exon 2 of the PML gene. Consequently, a reduction of MHC class I expression should have been observed, at variance from the results of this study. Data from We conclude that, in human cell lines, PML does not regulate the expression of MHC class I molecules. This is in accordance with the observation of patients with APL, in whom alteration of PML due to the t(15;17) translocation does not abrogate MHC class I expression on the leukemic cells.19
Submitted November 5, 2002; accepted December 10, 2002.
Prepublished online as Blood First Edition Paper, December 27, 2002; DOI 10.1182/blood-2002-11-3335.
Supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministero per l'Istruzione l'Università e la Ricerca Scientifica (MIUR), Progetto Finalizzato Ministero della Salute ("Alterazioni Geniche nelle Leucemie Acute"), and Compagnia di S. Paolo (E.C. and C.E.G.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Silvia Bruno, Department of Experimental Medicine, Section of Human Anatomy, Via De Toni, 14; 16132 Genova, Italy; e-mail: silvia.bruno{at}unige.it.
1. DeThé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684[CrossRef][Medline] [Order article via Infotrieve]. 2. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165-170[CrossRef][Medline] [Order article via Infotrieve]. 3. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 2001;20:7223-7233[CrossRef][Medline] [Order article via Infotrieve]. 4. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML/RAR in acute promyelocytic leukemia cells. Cell. 1994;76:345-356[CrossRef][Medline] [Order article via Infotrieve]. 5. Koken MH, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a retinoic-acid reversible fashion. EMBO J. 1994;13:1073-1083[Medline] [Order article via Infotrieve]. 6. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2:E85-E90[CrossRef][Medline] [Order article via Infotrieve]. 7. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. Embo J. 2002;21:3358-3369[CrossRef][Medline] [Order article via Infotrieve]. 8. Pearson M, Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene. 2001;20:7250-7256[CrossRef][Medline] [Order article via Infotrieve].
9.
Wang ZG, Delva L, Gaboli M, et al.
Role of PML in cell growth and the retinoic acid pathway.
Science.
1998;279:1547-1551 10. Grignani FR, Testa U, Rogaia D, et al. Effects on differentiation by the promyelocytic leukemia PML/RARa protein depend on the fusion of the PML protein-dimerization and RARa DNA binding domains. EMBO J. 1996;15:4949-4958[Medline] [Order article via Infotrieve]. 11. Rego E, Wang Z-G, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med. 2001;23:521-529.
12.
Grignani F, Valtieri M, Gabbianelli M, et al.
PML/RARa fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype.
Blood.
2000;96:1531-1537
13.
Alcalay M, Tomassoni L, Colombo E, et al.
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.
Mol Cell Biol.
1998;18:1084-1093 14. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet. 1998;20:259-265[CrossRef][Medline] [Order article via Infotrieve]. 15. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000;406:207-210[CrossRef][Medline] [Order article via Infotrieve].
16.
Zhong BS, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP.
Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis.
J Exp Med.
2000;191:631-640 17. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 2002;21:3358-3369[CrossRef][Medline] [Order article via Infotrieve]. 18. Zheng P, Guo Y, Niu Q, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature. 1998;396:373-376[CrossRef][Medline] [Order article via Infotrieve]. 19. Larghero J, Zassadowski F, Rousselot P, Padua RA, Degos L, Chomienne C. Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens. Leukemia. 1999;13:1295-1296[CrossRef][Medline] [Order article via Infotrieve]. 20. Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia. 1999;13:1175-1187[CrossRef][Medline] [Order article via Infotrieve]. 21. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498[CrossRef][Medline] [Order article via Infotrieve]. 22. Fagioli M, Alcalay M, Pandolfi PP, et al. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene. 1992;7:1083-1091[Medline] [Order article via Infotrieve]. 23. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001;9:2140-2151[CrossRef].
24.
Morgenstern JP, Land H.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acid Res.
1990;18:3587-3596 25. Pandolfi PP, Grignani F, Alcalay M, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene. 1991;6:1285-1292[Medline] [Order article via Infotrieve].
26.
Flenghi L, Fagioli M, Tomassoni L, et al.
Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia.
Blood.
1995;85:1871-1880 27. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nature Rev Genet. 2001;2:110-119[CrossRef][Medline] [Order article via Infotrieve].
28.
Elbashir SM, Lendeckel W, Tuschl T.
RNA interference is mediated by 21- and 22-nucleotide RNAs.
Genes Dev.
2001;15:188-200 29. Lavau C, Marchio A, Fagioli M, et al. The acute promyelocytic leukemia-associated PML gene is induced by interferon. Oncogene. 1995;11:871-876[Medline] [Order article via Infotrieve]. 30. Chan JY, Meng CL, To KF, et al. Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. Eur J Cancer. 2002;38:1600-1606[CrossRef][Medline] [Order article via Infotrieve]. 31. Zhang P, Chin W, Chow LT, et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer. 2000;85:599-605[CrossRef][Medline] [Order article via Infotrieve]. 32. Tian XX, Chan JY, Pang JC, et al. Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor. Br J Cancer. 1999;81:994-1001[CrossRef][Medline] [Order article via Infotrieve]. 33. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20:266-272[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Haupt, S. di Agostino, I. Mizrahi, O. Alsheich-Bartok, M. Voorhoeve, A. Damalas, G. Blandino, and Y. Haupt Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53 Cancer Res., June 1, 2009; 69(11): 4818 - 4826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crowder, O. Dahle, R. E. Davis, O. S. Gabrielsen, and S. Rudikoff PML mediates IFN-{alpha}-induced apoptosis in myeloma by regulating TRAIL induction Blood, February 1, 2005; 105(3): 1280 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, C. Shiels, P. Sasieni, P. J. Wu, S. A. Islam, P. S. Freemont, and D. Sheer Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions J. Cell Biol., February 16, 2004; 164(4): 515 - 526. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
20°C
followed by rehydration in phosphate-buffered saline (PBS) for
20 minutes at room temperature (for SP100). The last fixation procedure
was used for PML as well, in 2-color staining experiments, as no
significant difference was observed in the PML staining pattern between
paraformaldehyde and methanol fixation. After washing with PBS, primary
antibodies were added for 30 minutes at room temperature, followed by
fluorochrome-conjugated secondary antibodies for 30 minutes at room
temperature. Primary antibodies were omitted in controls. Nuclear
staining was revealed by 4',6-diamidino-2-phenylindole (DAPI, 1:200;
Sigma Chemical, St Louis, MO). Coverslips were mounted using Mowiol
488. Analyses were performed with an epifluorescence inverted
microscope (Olympus Optical, Hamburg, Germany), and images were
acquired using a chilled Hamamatsu CCD black-and-white camera and
processed with IPLab (Scanalytics, Fairfax, VA) and Adobe Photoshop software (San Jose, CA).
